Healthcare company Tevogen Bio revealed on Wednesday that it has filed its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to develop a COVID-19 treatment using proprietary antigen specific T cell technology.
In partnership with Dr Neal Flomenberg, a renowned bone marrow transplant expert and chair of the Department of Medical Oncology at Thomas Jefferson University, the company plans to evaluate T cell technology to treat hospitalized COVID-19 patients.
Utilising Tevogen's proprietary immunotherapy platform and Dr Flomenberg's expertise in research and the transplantation of T cells, the partnership will conduct clinical trials of T cell treatments for COVID-19. The T cells will be generated in the laboratory and administered to the very ill Corona patients. The body generates specific T cells to rid itself of viruses including COVID-19 in normal circumstances.
Additionally, Yale-trained infectious disease epidemiologist Dr Ryan Saadi is leading the company's efforts to develop a COVID-19 curative treatment.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients